Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.

Key inclusion Criteria: * Male patients with a diagnosis of schizophrenia no more than 5 calendar years (before screening); * Positive and negative symptoms assessed by PANSS; * Medically and psychiatrically stable; * On a stable dose of antipsychotic drugs; * Able to give fully informed written consent and likely to comply with the requirements of the trial. Key exclusion Criteria: * clinically relevant, as assessed by a physician, abnormal findings at the screening assessment; * sensitivity to excipients of the trial medication; * current use of contraindicated drugs; * participation in another clinical trial of unlicensed medicines within the previous 30 days; * loss of more than 400 mL blood, within the previous 3 months; history of drug or alcohol dependence in the last year; * significant acute or chronic illness; * significant medical history or concurrent medical condition that warrants exclusion; * objection by subject's physician